Second, together with Member States and the European Medicines Agency, the Commission has set up an executive steering group to monitor potential shortages of medicines due to COVID-19.
Teiseks on komisjon koos liikmesriikide ja Euroopa Ravimiametiga loonud juhtrühma, et jälgida COVID-19st tulenevat võimalikku ravimite nappust.